44 search results for: Atopic Dermatitis
Unpacking the Significant Burdens of Atopic Dermatitis
Dr. Lawrence Eichenfield shares the cumulative burdens faced by patients with atopic dermatitis.
Type 2 Inflammation Is a Driving Factor for Atopic Dermatitis and Related Comorbidities
Dr. Lawrence Eichenfield describes the pathophysiology of atopic dermatitis and how type 2 inflammation may sensitize patients to atopic comorbidities.
Insights From Dr Lawrence Eichenfield on the 2026 IEC Consensus Definition for Low Disease Activity and Remission for Atopic Dermatitis
Hear Dr. Lawrence Eichenfield share the recent consensus definitions from the International Eczema Council.
ADVENT On Air | Exploring The Urgency to Treat in Atopic Dermatitis
Professor Lisa Beck explores the chronic and persistent burden of atopic dermatitis (AD) as well as the concept of early intervention in patients with AD.
Atopic Dermatitis and the Growing Evidence for Its Association with Various Non-Atopic Systemic Diseases
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Prof. Amy Paller reviews emerging evidence linking atopic dermatitis not only to atopic comorbidities but to a range of non-atopic systemic diseases, including mental health disorders, neurodevelopmental conditions and impaired bone health.
Atopic Dermatitis and the Risk of Developing Other Atopic Diseases
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller discusses the significant risk of developing other atopic diseases among infants with early-onset atopic dermatitis.
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.
CLCI in Atopic Dermatitis Infographic
This infographic highlights how uncontrolled moderate‑to‑severe atopic dermatitis (AD) can lead to Cumulative Life Course Impairment (CLCI) by contributing to ongoing physical, psychological, and social burdens such as itch and sleep loss, impaired bone growth and mental health challenges. It emphasizes the importance of early and effective disease control to help reduce long‑term impact on patients.
ADVENT at EADV 2026
Please join the ADVENT program at EADV 2026 for educational sessions on AD, PN, and CSU! Experience 3 high-impact sessions led by world-renowned experts, bridging scientific innovation with real-world clinical outcomes.
Atopic Dermatitis Learning Hub
Welcome to the AD learning hub focused on key scientific education on atopic dermatitis, featuring ADVENT resources.
Atopic and Nonatopic Comorbidities in AD and the Importance of Early Intervention
In this soundbite video from the April 2025 ADVENT Forum in Lisbon, Portugal, Dr Amy Paller reviews the increased risk of atopic and nonatopic comorbidities associated with atopic dermatitis and discusses the potential of early intervention to mitigate their development.
Key Treatment Considerations for Management of Atopic Dermatitis in Children
In this highlight video from the October 2024 ADVENT symposium at EAPS in Vienna, Austria, Dr Perla Lansang reviews the key considerations for management of AD that is uncontrolled with topical therapies in children and the criteria to determine whether a patient is indicated for systemic therapy
